Skip to main content
SpringerLink
Log in

A Phase III Clinical Trial of Buserelin versus Danazol in the Treatment of Endometriosis

  • Chapter
GnRH Analogues in Cancer and Human Reproduction

  • 31 Accesses

Abstract

Hormonal treatments for endometriosis which are aimed at suppressing the pituitary-ovarian function (‘pseudomenopause’) seem to be superior to those regimes aimed at inducing a ‘pseudopregnancy’ state. Hypo-oestrogenism can cause atrophy and regression of endometriotic tissue.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Barbieri, RL, Evans, S and Kistner, RW (1982). Danazol in the treatment of endometriosis: analysis of 100 cases with a 4-year follow-up. Fertil Steril, 37, 737

    PubMed  CAS  Google Scholar 

  2. Lemay, A, Maheux, R, Faure, N, Jean, C and Fazekas, ATA (1984). Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LHRH) agonist (Buserelin) as a new therapeutic approach for endometriosis. Fertil Steril, 41, 863

    PubMed  CAS  Google Scholar 

  3. Shaw, RW and Matta, WHM (1986). Reversible pituitary ovarian suppression induced by an LHRH agonist in the treatment of endometriosis — comparison of two dose regimens. Clin Reprod Fertil, 4, 329

    PubMed  CAS  Google Scholar 

  4. Revised American Fertility Society Classification of Endometriosis (1985). Fertil Steril, 43, 351

    Google Scholar 

  5. Matta, WHM, Shaw, RW, Hesp, R and Katz, D (1987). Hypogonadism induced by luteinising hormone releasing hormone agonist analogues: effects of bone density in premenopausal women. Brit Med J, 294, 1523

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Academic Department of Obstetrics and Gynaecology, The Royal Free Hospital School of Medicine, London, NW3 2QG, UK

    Wassim H. M. Matta & Robert W. Shaw

Authors
  1. Wassim H. M. Matta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert W. Shaw
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institute of Biological Sciences, Syntex Research, Palo Alto, CA, 94304, USA

    Brian H. Vickery

  2. Institute of Endocrinology, Sheba Medical Center, Bar Ilan University, Remat Gan, 52621, Israel

    Bruno Lunenfeld

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Matta, W.H.M., Shaw, R.W. (1990). A Phase III Clinical Trial of Buserelin versus Danazol in the Treatment of Endometriosis. In: Vickery, B.H., Lunenfeld, B. (eds) GnRH Analogues in Cancer and Human Reproduction. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-2169-6_5

Download citation

  • DOI: https://doi.org/10.1007/978-94-009-2169-6_5

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-7474-2

  • Online ISBN: 978-94-009-2169-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation